Cellid, Co., Ltd.
Research Cellid, Co., Ltd. (299660.KQ) on Bullrun: market cap KRW 67.86B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker299660.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 67.86B
- Financial periodQ2 2026
- RevenueKRW 2.07B
- Net income-KRW 19.02B
- Free cash flow-KRW 6.83B
- Gross margin16.1%
Valuation Snapshot
latest market cap is KRW 67.86B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 67.86B | n/a | n/a | n/a |
Dividend history
About Cellid, Co., Ltd.
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cellid, Co., Ltd.'s market cap?
Cellid, Co., Ltd.'s market capitalization is KRW 67.86B.
What does Cellid, Co., Ltd. do?
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd.